Palvella Therapeutics (PVLA) Long-Term Debt Repayments (2014 - 2015)
Palvella Therapeutics (PVLA) reported Long-Term Debt Repayments of -$13230.0 for Q3 2015, down 106.98% year-over-year from $189420.0 in Q3 2014, and down 130.51% on a QoQ basis from $43365.0 in Q2 2015.
Palvella Therapeutics (PVLA) has 2 years of Long-Term Debt Repayments data on file, last reported at -$13230.0 in Q3 2015.
- Quarterly Long-Term Debt Repayments fell 106.98% year-over-year to -$13230.0 in Q3 2015, while the trailing twelve-month figure through Dec 2015 was $1.2 million (changed N/A YoY) and the FY2015 annual result came in at $1.2 million, up 537.93% from the prior year.
- Long-Term Debt Repayments declined to -$13230.0 in Q3 2015 per PVLA's latest filing, from $43365.0 in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $1.1 million in Q1 2015 and bottomed at -$13230.0 in Q3 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | -13,230.00 |
| Sep 30, 2015 | -13,230.00 |
| Jun 30, 2015 | 43,365.00 |
| Jun 30, 2015 | 43,365.00 |
| Mar 31, 2015 | 1.13 Mn |
| Mar 31, 2015 | 1.13 Mn |
| Sep 30, 2014 | 189,420.00 |
| Sep 30, 2014 | 189,420.00 |
| Jun 30, 2014 | 136,900.00 |
| Jun 30, 2014 | 136,900.00 |